Archford Capital Strategies’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-18,472
| Closed | -$1.13M | – | 322 |
|
|
2025
Q1 | $1.13M | Buy |
18,472
+6,664
| +56% | +$388K | 0.17% | 133 |
|
|
2024
Q4 | $668K | Buy |
11,808
+2
| +0% | +$112 | 0.1% | 161 |
|
|
2024
Q3 | $622K | Sell |
11,806
-8
| -0.1% | -$375 | 0.09% | 162 |
|
|
2024
Q2 | $491K | Sell |
11,814
-171
| -1% | -$7.65K | 0.08% | 179 |
|
|
2024
Q1 | $650K | Buy |
11,985
+127
| +1% | +$6.47K | 0.11% | 154 |
|
|
2023
Q4 | $608K | Sell |
11,858
-840
| -7% | -$44.1K | 0.11% | 153 |
|
|
2023
Q3 | $737K | Sell |
12,698
-259
| -2% | -$15.9K | 0.15% | 152 |
|
|
2023
Q2 | $839K | Sell |
12,957
-391
| -3% | -$26.2K | 0.16% | 145 |
|
|
2023
Q1 | $932K | Buy |
13,348
+195
| +1% | +$13.8K | 0.19% | 126 |
|
|
2022
Q4 | $946K | Buy |
13,153
+9
| +0.1% | +$679 | 0.22% | 110 |
|
|
2022
Q3 | $934K | Buy |
13,144
+105
| +0.8% | +$7.62K | 0.24% | 104 |
|
|
2022
Q2 | $1M | Buy |
13,039
+2
| +0% | +$152 | 0.25% | 98 |
|
|
2022
Q1 | $970K | Buy |
13,037
+289
| +2% | +$19.4K | 0.22% | 112 |
|
|
2021
Q4 | $795K | Sell |
12,748
-26
| -0.2% | -$1.52K | 0.18% | 141 |
|
|
2021
Q3 | $756K | Buy |
12,774
+122
| +1% | +$8.03K | 0.18% | 143 |
|
|
2021
Q2 | $845K | Sell |
12,652
-28
| -0.2% | -$1.83K | 0.21% | 125 |
|
|
2021
Q1 | $817K | Sell |
12,680
-18,994
| -60% | -$1.18M | 0.22% | 125 |
|
|
2020
Q4 | $1.98M | Sell |
31,674
-249
| -0.8% | -$15.3K | 0.46% | 56 |
|
|
2020
Q3 | $1.93M | Sell |
31,923
-960
| -3% | -$57.8K | 0.52% | 52 |
|
|
2020
Q2 | $1.93M | Sell |
32,883
-53
| -0.2% | -$3.17K | 0.58% | 48 |
|
|
2020
Q1 | $1.84M | Buy |
32,936
+9,126
| +38% | +$558K | 0.72% | 38 |
|
|
2019
Q4 | $1.53M | Buy |
23,810
+189
| +0.8% | +$10.8K | 0.53% | 55 |
|
|
2019
Q3 | $1.2M | Sell |
23,621
-87
| -0.4% | -$4.09K | 0.45% | 64 |
|
|
2019
Q2 | $1.07M | Sell |
23,708
-34
| -0.1% | -$1.58K | 0.39% | 75 |
|
|
2019
Q1 | $1.13M | Sell |
23,742
-109
| -0.5% | -$5.43K | 0.42% | 70 |
|
|
2018
Q4 | $1.24M | Sell |
23,851
-79
| -0.3% | -$4.25K | 0.5% | 51 |
|
|
2018
Q3 | $1.49M | Sell |
23,930
-857
| -3% | -$50.9K | 0.54% | 49 |
|
|
2018
Q2 | $1.37M | Buy |
24,787
+1,115
| +5% | +$60.2K | 0.48% | 54 |
|
|
2018
Q1 | $1.45M | Buy |
23,672
+3,105
| +15% | +$200K | 0.6% | 53 |
|
|
2017
Q4 | $1.26M | Sell |
20,567
-3,962
| -16% | -$248K | 0.47% | 63 |
|
|
2017
Q3 | $1.56M | Buy |
24,529
+12,056
| +97% | +$704K | 0.59% | 53 |
|
|
2017
Q2 | $695K | Sell |
12,473
-2,932
| -19% | -$160K | 0.27% | 122 |
|
|
2017
Q1 | $835K | Sell |
15,405
-406
| -3% | -$22.3K | 0.31% | 111 |
|
|
2016
Q4 | $922K | Buy |
15,811
+427
| +3% | +$23.3K | 0.39% | 93 |
|
|
2016
Q3 | $828K | Buy |
15,384
+12,231
| +388% | +$786K | 0.34% | 110 |
|
|
2016
Q2 | $232K | Sell |
3,153
-9,405
| -75% | -$665K | 0.12% | 141 |
|
|
2016
Q1 | $802K | Sell |
12,558
-2,452
| -16% | -$155K | 0.38% | 91 |
|
|
2015
Q4 | $910K | Buy |
15,010
+13,215
| +736% | +$873K | 0.41% | 81 |
|
|
2015
Q3 | $106K | Buy |
1,795
+65
| +4% | +$4.12K | 0.08% | 148 |
|
|
2015
Q2 | $115K | Hold |
1,730
| – | – | 0.08% | 145 |
|
|
2015
Q1 | $112K | Buy |
1,730
+339
| +24% | +$21.2K | 0.08% | 156 |
|
|
2014
Q4 | $82K | Hold |
1,391
| – | – | 0.06% | 165 |
|
|
2014
Q3 | $71K | Hold |
1,391
| – | – | 0.06% | 174 |
|
|
2014
Q2 | $67.5K | Sell |
1,391
-6,417
| -82% | -$316K | 0.05% | 188 |
|
|
2014
Q1 | $406K | Buy |
+7,808
| New | +$415K | 0.34% | 88 |
|
Other funds holding BMY
Archford Capital Strategies's BMY Position: Q2 2025 in Review
Archford Capital Strategies sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 18,472 shares — an estimated $1.13M sold.
Archford Capital Strategies first reported a position in BMY in Q1 2014 and held it in 45 quarters. The position peaked at $1.98M in Q4 2020. 2,293 funds tracked by Wall St. Rank hold BMY as of Q2 2025.
- Archford Capital Strategies reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
- Archford Capital Strategies sold 18,472 Bristol-Myers Squibb shares in Q2 2025, an estimated $1.13M.
- Archford Capital Strategies first reported a position in Bristol-Myers Squibb in Q1 2014 and held it in 45 quarters.
- Archford Capital Strategies's Bristol-Myers Squibb position peaked at $1.98M in Q4 2020.
- 2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.
Based on Archford Capital Strategies's 13F filing for Q2 2025, filed 17 Jul 2025.